Harvey AI vs Causaly (2026)

Harvey AI

by Harvey

Causaly

by Causaly

Pros

• ✓Purpose-built legal training and workflow design -- Harvey is trained on legal corpora and designed around attorney-client privilege, matter confidentiality, and citation standards that general AI platforms cannot replicate without significant prompt engineering
• ✓Zero data training guarantee by contract -- Harvey is one of the few enterprise AI platforms that contractually prohibits use of customer data for model training by default, critical for firms managing privileged communications
• ✓Action-level DMS integration creates and updates documents in iManage, NetDocuments, and SharePoint -- not a read-only research tool, Harvey participates in the full document lifecycle of a legal matter

Limitations

• ⚠Enterprise-only pricing with no self-serve option -- Harvey does not publish pricing and requires a sales process; typical annual contracts run six figures, making it inaccessible for small firms and solo practitioners
• ⚠Deployment requires 4-12 weeks including firm security review, custom configuration, and integration work -- not a tool teams can activate and evaluate quickly, which creates friction for firms weighing AI adoption decisions
• ⚠Performance is strongest on common law jurisdictions and English-language legal documents -- coverage for non-English jurisdictions, civil law systems, and highly specialised practice areas may require additional configuration and validation

Pros

• ✓Biomedical knowledge graph is genuinely differentiated — Causaly's proprietary graph captures gene/protein/disease/drug relationships that horizontal AI research tools cannot match, materially better evidence-based R&D outcomes than tools relying purely on text-based literature search
• ✓Agentic AI for specific R&D use cases — AI agents purpose-built for target identification, drug repositioning, mechanism investigation, and safety assessment provide materially better outcomes than general-purpose research agents that lack pharmaceutical R&D specialization
• ✓Strong life sciences enterprise reference base — substantial pharmaceutical and biotech customer adoption with Pulitzer-winning thought leadership content provides procurement validation that de-risks enterprise R&D investments

Limitations

• ⚠Enterprise-only pricing inaccessible to academic researchers and startups — Causaly deployments at $200K+/year exclude individual researchers, small biotech startups, and academic research teams that need lighter-weight life sciences AI tools
• ⚠Specialized for life sciences limits cross-domain value — Causaly is purpose-built for biomedical R&D and provides no value for non-life-sciences research domains, hard constraint for organizations with diverse research needs
• ⚠Implementation complexity from R&D-specific configuration — biomedical knowledge graph setup, AI agent configuration for R&D workflows, and integration with proprietary pharmaceutical databases require sustained life sciences expertise beyond just technology deployment